Qubigen

Qubigen’s core business is to use Federated AI to accelerate hit-to-lead and candidate optimization through secure, privacy-preserving analysis of molecular data, advanced virtual screening, and GPU-parallelized quantum chemistry in an end-to-end, real-time application-specific workflow, leading to actionable compounds for tough diseases. Qubigen's Federated AI accelerates drug design with secure, real-time analysis of molecular data, virtual screening, and GPU-powered quantum chemistry, providing an end-to-end, application-specific platform that delivers actionable compounds for challenging diseases. Federated AI Engines for drug design enable secure collaboration, transcending institutional data firewalls. Qubigen's FedAIDD can leverage global data without actually moving or seeing it, to build the most intelligent, secure, disease-agnostic AI engines in drug design. Qubigen’s edge lies in its end-to-end, application-specific workflow and enabling infrastructure. Qubigen transforms that access into actionable, optimized drug candidates, offering a “moat” through patents and domain expertise.